TORCH Infections: Diagnostic and Treatment Approach
Direct Recommendation
For suspected TORCH infections, abandon the outdated "TORCH panel" approach and instead pursue targeted, pathogen-specific testing based on clinical presentation, maternal history, and fetal/neonatal findings, with congenital toxoplasmosis and CMV requiring the most aggressive diagnostic and therapeutic interventions. 1
Diagnostic Strategy
Abandon Universal TORCH Testing
The traditional "TORCH test" is no longer appropriate and should be replaced with specific testing for specific pathogens under well-defined circumstances 2. Testing should be driven by either maternal symptoms or fetal abnormalities, not performed as a routine battery 3.
When to Test: Maternal vs Fetal Indications
Maternal-related indications (higher yield - 2.6% positive rate):
- Thrombocytopenia (7.1% positive rate)
- Elevated liver enzymes (3.0% positive rate)
- Fever with rash
- Gastroenteritis symptoms
Fetal-related indications (lower yield - 0.8% positive rate):
- Intrauterine growth restriction
- Intracranial calcifications
- Ventriculomegaly/hydrocephalus
- Hepatosplenomegaly
- Polyhydramnios/oligohydramnios
The clinical yield for nonspecific sonographic features alone is low 3. However, maternal symptoms should prompt immediate CMV and Toxoplasma testing specifically.
Congenital Toxoplasmosis: The Most Critical TORCH Component
Maternal Diagnosis and Treatment
For pregnant women with suspected acute toxoplasmosis:
Confirm maternal infection with reference laboratory testing (not just screening tests)
Spiramycin for low-risk scenarios 1:
- Negative amniotic fluid PCR
- Negative fetal ultrasound
- Low suspicion of fetal infection
- Dose: 1g (3 million IU) PO three times daily = 9 million IU/day
- Available only through FDA Investigational New Drug process (301-796-1600)
- Continue until delivery
Pyrimethamine + Sulfadiazine + Folinic acid for high-risk scenarios 1:
- ≥18 weeks gestation AND any of:
- Positive amniotic fluid PCR
- Abnormal fetal ultrasound suggestive of congenital toxoplasmosis
- Confirmed acute infection at/after 18 weeks
Maternal dosing:
- Pyrimethamine: 100mg/day PO divided twice daily × 2 days, then 50mg/day
- Sulfadiazine: 75mg/kg loading dose, then 100mg/kg/day divided twice daily (max 4g/day)
- Folinic acid: Must be given concurrently
- ≥18 weeks gestation AND any of:
Newborn Evaluation for Suspected Congenital Toxoplasmosis
Complete diagnostic workup includes 1:
Clinical assessment:
- Detailed physical examination
- Neurologic evaluation every 2-3 months first year
- Ophthalmologic examination by retinal specialist
Laboratory testing:
- Toxoplasma IgG, IgM (ISAGA), and IgA in parallel with maternal samples
- Peripheral blood, urine, and CSF PCR for Toxoplasma
- Complete blood count and liver function tests
Imaging:
- Head CT (or ultrasound if low suspicion)
- Abdominal ultrasound
- Brainstem auditory evoked responses
Critical timing considerations 1:
- If positive IgM/IgA at birth, repeat ≥7 days after any blood product transfusion
- If concern for maternal blood contamination, repeat ≥5 days after birth (IgM half-life) or ≥10 days (IgA half-life)
- For very late gestational infections, initially negative IgM/IgA may require repeat testing at 2-4 weeks
Newborn Treatment Protocol
For confirmed or suspected congenital toxoplasmosis, treat for 12 months 1:
Pyrimethamine:
- 2mg/kg/day PO divided twice daily × 2 days
- Then 1mg/kg/day PO daily from day 3 to 2 months (extend to 6 months if symptomatic)
- Then 1mg/kg/day PO three times weekly for remainder of year
Sulfadiazine: 100mg/kg/day PO divided twice daily
Folinic acid (leucovorin): 10mg three times weekly
Corticosteroids: Consider if severe chorioretinitis or CSF protein ≥1g/dL (start after 72 hours of anti-Toxoplasma therapy)
Diagnostic Criteria for Congenital Toxoplasmosis 1
Diagnosis confirmed by ANY of:
- Persistence of positive Toxoplasma IgG beyond 12 months (gold standard)
- Positive IgG with positive IgM and/or IgA
- Positive PCR from amniotic fluid, blood, CSF, urine, or other fluids
- Positive neonatal IgG (but negative IgM/IgA) + maternal acute infection + clinical manifestations
When Treatment May Be Deferred (Use Cautiously in US) 1
All criteria must be met 1:
- Maternal infection acquired in first or second trimester
- Negative amniotic fluid PCR at ≥18 weeks
- No laboratory evidence in newborn (positive IgG at lower titers than maternal, but negative IgM/IgA)
- No clinical/radiologic signs at birth
Critical caveat: This approach is used in Europe where mothers received antepartum treatment. In the US, where most mothers did NOT receive antepartum treatment, defer treatment only with extreme caution. For third-trimester maternal infections, even negative amniotic fluid PCR cannot exclude fetal infection 1.
Long-term Monitoring for Treated Infants 1
After completing 12 months of treatment:
- Clinical + serologic + ophthalmologic follow-up every 3 months for second year
- Every 6 months for third year
- Yearly thereafter, indefinitely (75% of chorioretinal lesions appear after 7 months of age, 50% after 3 years, 25% after 8 years) 1
For infants unlikely to be infected:
- Serologic follow-up every 4-6 weeks until IgG undetectable 1
- If subsequent testing indicates infection, initiate full treatment
Other TORCH Pathogens: Key Points
Cytomegalovirus (CMV)
- Most common congenital infection globally 4
- Maternal treatment uptake significantly lower than toxoplasmosis (52.2% vs 100%) 5
- Higher detection rate with maternal-related indications (thrombocytopenia, elevated liver enzymes) 3
Emerging Pathogens
The TORCH acronym no longer encompasses the full spectrum: Zika virus, SARS-CoV-2, syphilis, varicella-zoster, HIV, parvovirus B19, and lymphocytic choriomeningitis virus must be considered 4, 6.
Common Pitfalls to Avoid
Never order a "TORCH panel" - this outdated approach leads to misinterpretation and unnecessary testing 2
Don't interpret neonatal serology without maternal samples - transplacental IgG transfer makes interpretation impossible without parallel maternal testing 1
Don't assume negative amniotic fluid PCR excludes third-trimester infections - sensitivity decreases with later gestational age 1
Don't stop ophthalmologic surveillance after infancy - most chorioretinal lesions appear years after birth 1
Don't use spiramycin if fetal infection is documented or suspected - switch to pyrimethamine/sulfadiazine/folinic acid 1
Younger women are most susceptible to acute TORCH infections and require targeted screening 6